Pancreatic Cancer Market Research Report- Forecast till 2027

Pancreatic Cancer Market Information: By Type (Endocrine Pancreas Cancer and Exocrine Pancreas Cancer), Treatment (Hormone Therapy, Biologic Therapy, and Targeted Therapy), End User (Hospitals & Clinics and Research Institute)- Forecast till 2027

ID: MRFR/Pharma/1107-HCR | August 2022 | Region: Global | 110 pages

Impact of COVID-19 Global Pancreatic Cancer Market

The COVID-19 epidemic has been straining healthcare workflow across the globe. The disease has forced various industries to temporarily shut its doors including many healthcare subdomains. Treatment for pancreatic cancer has been one of the concerns as the current focus is on the treatment of COVID-19 patients. The pancreatic cancer market has been negatively impacted by COVID-19.  It is expected that many patients with pancreatic cancer will suffer from the disease if the crisis for COVID-19 continues to demand the major share of clinical time and resources. It is one of the major challenges for healthcare professionals to choose between dealing with acutely unwell COVID-19 patients and those patients who could have elective surgery for operable pancreatic cancer. That’s the red alert from Pancreatic Cancer Action, which has been swamped with inquiries from people whose operations and chemotherapy have been canceled in recent weeks.

Diagnoses for pancreatic cancer are slackening, as individuals find it challenging to access primary care for a referral and all non-emergency endoscopies. The mainstay detecting pancreatic cancer has halted due to the risk of the aerosol transmission of the novel coronavirus. The majority of the hospitals have stopped immune system-mapping courses of chemotherapy, moreover, patients themselves are concerned about attending hospital appointments due to the high risk of getting infected by a coronavirus. Simultaneously, oncology healthcare professionals are being diverted to the COVID-19 front line, allowing a smaller number of doctors and nurses to manage chemotherapies to those patients that can continue with treatment.

Organizations Taking Steps for the Treatment of Pancreatic Cancer

Various organizations are taking steps for the treatment of cancer. For example, the American Society of Clinical Oncology (ASCO) has developed the patient care guidelines for the treatment of patients suffering from cancer. Using proper measures and following national and international guidelines, Tata Memorial Centre one of India’s largest cancer centers has decided to continue providing cancer care using a proactive and multipronged approach. Moreover, the European Society for Medical Oncology has provided the following steps for the treatment of cancer

High priority: These appointments will likely go ahead as planned

High/medium priority: These appointments will be conducted via telephone where possible, or could be relocated to a local healthcare center or cancer clinic

Medium priority: These appointments may be conducted via telephone (where possible), relocated to a local healthcare center or cancer clinic or may be delayed for a short time (no more than 6–8 weeks)

Low priority: These appointments may be conducted via telephone or delayed for the duration of the COVID-19 pandemic.

The pancreatic cancer market has been negatively impacted by the COVID-19. This impact was visible at the end of the first quarter and the start of the second quarter of 2020. However, currently, various organizations by following proper guidelines and measures have started the treatment of pancreatic cancer. Steadily it is expected the market for pancreatic cancer to resume normally by the end of 2020 and bounce back with a high growth rate in the year 2021.